ArticleDiscover oncology2026
Pan-cancer prioritization of CCDC69 reveals an immune-enriched and therapeutically sensitive breast cancer phenotype.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundCoiled-coil domain-containing protein 69 (CCDC69) has been implicated in tumor biology, but its pan-cancer immunogenomic context and relevance to breast cancer remain insufficiently defined.
methodsWe integrated The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) transcriptomes, paired tumor-normal comparisons, diagnostic modeling, survival analyses, copy-number and genomic-instability profiling, immune-cycle and immune-infiltration analyses, single-cell and spatial transcriptomic datasets, pathway enrichment, immunotherapy cohorts, pharmacogenomic resources and molecular docking to characterize CCDC69 across cancers and in breast invasive carcinoma (BRCA).
resultsCCDC69 was broadly dysregulated across cancers and showed cancer-type-dependent diagnostic value. Pan-cancer survival analyses revealed context-specific prognostic effects, with BRCA showing consistent favorable associations for disease-specific survival (DSS), disease-free interval (DFI) and progression-free interval (PFI). Further analyses linked CCDC69 to copy-number states, stemness, genomic instability and multiple immune phenotypes. Integrated prioritization highlighted BRCA as a representative tumor context. In BRCA, higher CCDC69 expression was associated with less advanced clinicopathological features, immune-enriched microenvironments, increased cancer-immunity-cycle activity, diverse immune-cell infiltration and compartment-specific expression across tumor, immune and stromal regions. Pathway analyses connected CCDC69 with immune activation, interferon response and lymphocyte-related programs, while showing inverse associations with proliferation, DNA repair and cell-cycle signatures. Immunotherapy and drug-sensitivity analyses suggested context-dependent response-stratification and therapeutic relevance.
conclusionCCDC69 delineates an immune-active, favorable-risk BRCA state with potential prognostic and therapy-related value, warranting experimental and clinical validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.